{"product_id":"mdr-artikel88-trendrapportering-tillbudsanalys-capa","title":"MDR Article 88 – Trend Reporting, Supply Analysis and CAPA Register | Word\/PDF\/Excel","description":"\u003cdiv lang=\"sv\" class=\"mb-product-copy\"\u003e\n\n\u003cp\u003e\u003cstrong\u003ePay attention to recurring offers involving medical devices – and document the difference between a frequency signal, statistical significance, and an actual reporting obligation.\u003c\/strong\u003e This document package supports MDR manufacturers, quality managers, and vigilance functions in their work with Article 88 of Regulation (EU) 2017\/745. With Word, PDF, and Excel, you can follow a traceable chain from event classification and planned statistical method to a potential regulatory report, corrective actions, and verified effectiveness.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eQuick facts:\u003c\/strong\u003e Swedish\/EU law • five Swedish work templates, a Swedish guide, and a separate English User Guide • 7 editable DOCX + 7 searchable\/printable PDFs + 1 XLSX with 9 tabs • \u003cstrong\u003e15 files\u003c\/strong\u003e in a digital ZIP delivery. Searchable PDFs are not interactively fillable.\u003c\/p\u003e\n\n\u003csection aria-label=\"Package contents\" style=\"border:2px solid #7FAFC8;background:#EAF4FA;padding:18px;border-radius:12px;margin:18px 0\"\u003e\u003ch2\u003ePackage contents\u003c\/h2\u003e\n\n\u003cp\u003eSeven document types: offer triage, trend plan with baseline, trend investigation and benefit–risk decision, regulatory reporting and evidence, CAPA\/effectiveness verification, a Swedish user guide, and an English User Guide. Each document is provided in Word and searchable PDF. In addition, there is a Swedish Excel register with nine tabs. Total: \u003cstrong\u003e7 DOCX + 7 PDF + 1 XLSX = 15 customer files\u003c\/strong\u003e. The PDF version of a Word document is not a separate legal document.\u003c\/p\u003e\u003c\/section\u003e\n\u003csection aria-label=\"What the files contain\" style=\"border:2px solid #7FAFC8;background:#F7FAFD;padding:18px;border-radius:12px;margin:18px 0\"\u003e\u003ch2\u003eWhat the files contain\u003c\/h2\u003e\n\n\u003cp\u003eForm fields for product\/UDI, risk class, event ID, actual knowledge occasion, Article 87 triage, baseline, comparable exposure volume, predefined method, significance test, benefit–risk assessment, regulatory decision, and actual reporting confirmation. Excel distinguishes between \u003cstrong\u003erecorded event, numerical signal, expert risk decision, actually submitted report, and verified CAPA effect\u003c\/strong\u003e. Nothing is sent automatically.\u003c\/p\u003e\u003c\/section\u003e\n\u003ch2\u003eWhen might an MDR manufacturer need this package?\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eExample 1:\u003c\/strong\u003e A manufacturer of medical measuring instruments sees more service and user complaints. They need to distinguish changed usage volume from a genuinely increasing frequency and check whether the events are serious under Article 87 or fall under Article 88. \u003cstrong\u003eExample 2:\u003c\/strong\u003e A manufacturer is following up on an expected adverse effect and needs a pre-defined baseline, relevant risk documentation, and a documented statistical method. \u003cstrong\u003eExample 3:\u003c\/strong\u003e After an action, the quality function needs to show that the change actually had the intended effect, not just that a CAPA was marked as completed.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eProduct scope:\u003c\/strong\u003e Designed for the manufacturer's workflow under MDR 2017\/745. IVD products are covered by IVDR 2017\/746, with their own articles and reporting provisions. Independent distributors and healthcare providers have different roles and obligations. The template does not provide CE certification, laboratory results, independent statistical expert analysis, or regulatory approval.\u003c\/p\u003e\n\n\u003ch2\u003eAll files and functions\u003c\/h2\u003e\n\n\u003cdiv style=\"overflow-x:auto\"\u003e\u003ctable\u003e\n\n\u003cthead\u003e\u003ctr\u003e\n\n\u003cth scope=\"col\"\u003eDocument\u003c\/th\u003e\n\n\u003cth scope=\"col\"\u003eFunction\u003c\/th\u003e\n\n\u003cth scope=\"col\"\u003eLanguage\u003c\/th\u003e\n\n\u003cth scope=\"col\"\u003eFormat\u003c\/th\u003e\n\n\n\u003c\/tr\u003e\u003c\/thead\u003e\n\n\u003ctbody\u003e\n\n\u003ctr\u003e\n\n\u003cth scope=\"row\"\u003eOffer triage – Article 87 or 88\u003c\/th\u003e\n\n\u003ctd\u003eAssess whether a suspected serious incident must be escalated immediately.\u003c\/td\u003e\n\n\u003ctd\u003eSwedish\u003c\/td\u003e\n\n\u003ctd\u003eDOCX + searchable PDF\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003cth scope=\"row\"\u003eTrend plan, baseline, and method\u003c\/th\u003e\n\n\u003ctd\u003eDefine product group, time period, exposure, and statistical method.\u003c\/td\u003e\n\n\u003ctd\u003eSwedish\u003c\/td\u003e\n\n\u003ctd\u003eDOCX + searchable PDF\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003cth scope=\"row\"\u003eTrend investigation and benefit–risk decision\u003c\/th\u003e\n\n\u003ctd\u003eKeep observed increase, significance, and legal criteria separate.\u003c\/td\u003e\n\n\u003ctd\u003eSwedish\u003c\/td\u003e\n\n\u003ctd\u003eDOCX + searchable PDF\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003cth scope=\"row\"\u003eReporting decision and evidence\u003c\/th\u003e\n\n\u003ctd\u003eDocument regulatory pathway, actual submission, and receipt confirmation.\u003c\/td\u003e\n\n\u003ctd\u003eSwedish\u003c\/td\u003e\n\n\u003ctd\u003eDOCX + searchable PDF\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003cth scope=\"row\"\u003eCAPA and effectiveness verification\u003c\/th\u003e\n\n\u003ctd\u003eDistinguish completed safety action from verified effectiveness.\u003c\/td\u003e\n\n\u003ctd\u003eSwedish\u003c\/td\u003e\n\n\u003ctd\u003eDOCX + searchable PDF\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003cth scope=\"row\"\u003eSwedish user guide\u003c\/th\u003e\n\n\u003ctd\u003eSeven work steps, legal references, and clear limitations.\u003c\/td\u003e\n\n\u003ctd\u003eSwedish\u003c\/td\u003e\n\n\u003ctd\u003eDOCX + searchable PDF\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003cth scope=\"row\"\u003eEnglish User Guide\u003c\/th\u003e\n\n\u003ctd\u003eInstructions in English for the Swedish work templates.\u003c\/td\u003e\n\n\u003ctd\u003eEnglish\u003c\/td\u003e\n\n\u003ctd\u003eDOCX + searchable PDF\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\u003ctr\u003e\n\n\u003cth scope=\"row\"\u003eExcel – trend and CAPA register\u003c\/th\u003e\n\n\u003ctd\u003eNine tabs with baselines, offers, trends, decisions, and actions.\u003c\/td\u003e\n\n\u003ctd\u003eSwedish\u003c\/td\u003e\n\n\u003ctd\u003eXLSX\u003c\/td\u003e\n\n\n\u003c\/tr\u003e\n\n\n\u003c\/tbody\u003e\n\n\n\u003c\/table\u003e\u003c\/div\u003e\n\n\u003ch2\u003eThe nine-tab Excel tool\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eRead me, Overview, Products, Signals, Baselines, Trends, Risk Decisions, Actions, Sources.\u003c\/strong\u003e The eight administrative compilations show, for example, registered products, received events, cases for urgent Article 87 review, trends over the entered baseline, undetermined ratios, completed expert assessments, actually submitted reports, and verified CAPA effects.\u003c\/p\u003e\n\n\u003cp\u003eThe simple trend calculation normalizes the number of events per 1,000 manually entered exposure units. The comparison gives \u003cstrong\u003e\"Above baseline – manual review\"\u003c\/strong\u003e, \u003cstrong\u003e\"Not above baseline – still review\"\u003c\/strong\u003e, or \u003cstrong\u003e\"Not assessed\"\u003c\/strong\u003e. The ratio is \u003cstrong\u003enot\u003c\/strong\u003e a significance test, p-value, confidence interval, or medical device risk decision. The baseline and statistical method must be documented in the manufacturer's PMS plan\/technical documentation. If the exposure denominator is zero or missing, no false sense of safety is created.\u003c\/p\u003e\n\n\u003ch2\u003eHow the package is used – from offer to verified CAPA\u003c\/h2\u003e\n\n\u003col\u003e\n\n\u003cli\u003eImmediately assess whether it may be a serious incident under MDR Article 87. If so: follow the separate urgent reporting pathway.\u003c\/li\u003e\n\n\u003cli\u003eRecord the product, event category, risk file, relevant PMS version, and the actual knowledge occasion.\u003c\/li\u003e\n\n\u003cli\u003eUse the pre-planned observation period, statistical method, and product\/event-specific baseline.\u003c\/li\u003e\n\n\u003cli\u003eDocument the actual exposure denominator and any differences in reporting rate and product mix.\u003c\/li\u003e\n\n\u003cli\u003eHave qualified personnel assess statistical significance, the benefit–risk ratio, and whether an unacceptable risk may arise.\u003c\/li\u003e\n\n\u003cli\u003eIf there is a reporting obligation: follow the \u003ca href=\"https:\/\/www.lakemedelsverket.se\/sv\/medicinteknik\/folj-upp-anvandning\/rapportering-av-allvarliga-tillbud\"\u003eSwedish Medical Products Agency's current instructions\u003c\/a\u003e, and record only the actually submitted report and actual receipt as completed.\u003c\/li\u003e\n\n\u003cli\u003eSeparate the corrective action, its implementation, and actual effectiveness verification. Update relevant PMS and risk files.\u003c\/li\u003e\n\n\n\u003c\/ol\u003e\n\n\u003ch2\u003eThe law: MDR Articles 83, 87, 88, and 89\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticles 83 and 84:\u003c\/strong\u003e The manufacturer shall have a risk-based post-market surveillance system and a PMS plan. Article 88 requires the manufacturer to specify in the plan how affected incidents shall be handled, which method is used for a statistically significant increase, and the chosen observation period. \u003ca href=\"https:\/\/eur-lex.europa.eu\/legal-content\/SV\/TXT\/?uri=CELEX%3A02017R0745-20260101\"\u003eOfficial consolidated MDR text in Swedish\u003c\/a\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle 87 – serious incidents:\u003c\/strong\u003e Serious incidents and certain corrective safety actions have a separate and urgent reporting procedure. The \u003ca href=\"https:\/\/www.lakemedelsverket.se\/sv\/medicinteknik\/folj-upp-anvandning\/rapportering-av-allvarliga-tillbud\"\u003eSwedish Medical Products Agency\u003c\/a\u003e describes maximum timeframes of normally two, ten, or fifteen calendar days depending on the consequence and circumstances; the obligation to report may arise earlier. A suspected serious incident must not wait in an Article 88 trend queue.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle 88 – trends:\u003c\/strong\u003e The reportable situation is not merely that the number of complaints has increased. A \u003cstrong\u003estatistically significant increase in frequency or severity\u003c\/strong\u003e of non-serious incidents or expected adverse effects is required, which may affect the benefit–risk analysis in the prescribed manner and has led or may lead to risks that are unacceptable in relation to the intended benefit. Compare with the foreseeable frequency or severity over the period specified in the manufacturer's documentation.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eArticle 89:\u003c\/strong\u003e Special requirements apply to analysis and corrective safety actions after serious incidents. Creating a CAPA log does not mean that the requirements for a field safety action or reporting are thereby met.\u003c\/p\u003e\n\n\u003ch2\u003eEUDAMED 2026 – what applies to trend reporting?\u003c\/h2\u003e\n\n\u003cp\u003eThe European Commission confirms that four EUDAMED modules became mandatory on \u003cstrong\u003e28 May 2026\u003c\/strong\u003e: actors, UDI\/products, notified bodies\/certificates, and market surveillance. However, the module for \u003cstrong\u003evigilance and post-market surveillance was still under development on 17 November 2026\u003c\/strong\u003e. \u003ca href=\"https:\/\/health.ec.europa.eu\/medical-devices-eudamed\/overview_en\"\u003eThe European Commission's current module list\u003c\/a\u003e. Therefore, check the national reporting pathway and the actual system status for each case. The Excel register is never an EUDAMED or MIR form.\u003c\/p\u003e\n\n\u003ch2\u003ePersonal data and statistical limitations\u003c\/h2\u003e\n\n\u003cp\u003eUse only the product and case references that are necessary. Medical device incidents may contain sensitive health data requiring special data protection under GDPR. Patient records and directly identifying information should not be placed in an unprotected workbook. \u003cstrong\u003eIndependent statistical expert validation is not included\u003c\/strong\u003e, nor is a valid Article 88 report, a regulatory submission, or a regulatory signature.\u003c\/p\u003e\n\n\u003ch2\u003eComplement with related templates\u003c\/h2\u003e\n\n\u003cp\u003eFor \u003ca href=\"\/en\/products\/eudamed-2026-legacy-udi-registrering-28-november\"\u003eEUDAMED registration and UDI\u003c\/a\u003e, there is a separate product. \u003ca href=\"\/en\/products\/medicinteknik-leveransavbrott-mdr-ivdr-artikel-10a\"\u003eMDR\/IVDR Article 10a – supply interruption\u003c\/a\u003e covers interruption information, not incident trends. For structured risk analysis, there is \u003ca href=\"\/en\/products\/fmea-feleffektanalys-mall-excel-2026-2027\"\u003eFMEA and action register\u003c\/a\u003e. This product covers the narrower \u003cstrong\u003eArticle 88 process\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2\u003eFrequently Asked Questions (FAQ)\u003c\/h2\u003e\n\n\u003ch3\u003eMust all increases in complaints be reported under Article 88?\u003c\/h3\u003e\n\n\u003cp\u003eNo. A relevant statistically significant increase and the other criteria in Article 88 are required, including the assessment of benefit–risk and unacceptable risk. An Excel ratio over 1 is not sufficient.\u003c\/p\u003e\n\n\u003ch3\u003eCan we handle serious incidents via the same Excel tab?\u003c\/h3\u003e\n\n\u003cp\u003eRegistration can be used for traceability, but serious and potentially serious events must first be reviewed and, if necessary, reported urgently under Article 87. Trend reporting must not delay that process.\u003c\/p\u003e\n\n\u003ch3\u003eDoes the workbook calculate statistical significance?\u003c\/h3\u003e\n\n\u003cp\u003eNo. Excel calculates the frequency per 1,000 specified exposure units and compares it with a manually entered baseline. The statistical method, significance, and clinical risk are assessed by the manufacturer according to the PMS plan.\u003c\/p\u003e\n\n\u003ch3\u003eDoes this product also apply to IVD products?\u003c\/h3\u003e\n\n\u003cp\u003eNot without adaptation. In vitro diagnostic products are regulated primarily by IVDR 2017\/746 with different article numbers and special obligations.\u003c\/p\u003e\n\n\u003ch3\u003eCan Excel submit a report to EUDAMED or the Swedish Medical Products Agency?\u003c\/h3\u003e\n\n\u003cp\u003eNo. No file automates a regulatory submission. Document the current channel, the actual submission date, and actual receipt confirmation when available.\u003c\/p\u003e\n\n\u003ch3\u003eAre all work documents also available in English?\u003c\/h3\u003e\n\n\u003cp\u003eNo. Five Swedish operational templates, a Swedish user guide, and a separate English User Guide are included. The English guide is an instruction, not fully translated operational templates.\u003c\/p\u003e\n\n\u003ch3\u003eAre the PDF versions digitally fillable?\u003c\/h3\u003e\n\n\u003cp\u003eNo. They are searchable and can be printed. DOCX or XLSX is used for editing.\u003c\/p\u003e\n\n\u003ch3\u003eHas the product been reviewed by a lawyer or medical device expert?\u003c\/h3\u003e\n\n\u003cp\u003eNo. Only internal AI-assisted legal source control and technical documentation\/Excel QA have been carried out. Independent legal, medical device, or statistical expert review has not been performed.\u003c\/p\u003e\n\n\u003ch2\u003eSources and version\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eVersion 1.0, 17 November 2026.\u003c\/strong\u003e Official sources: \u003ca href=\"https:\/\/eur-lex.europa.eu\/legal-content\/SV\/TXT\/?uri=CELEX%3A02017R0745-20260101\"\u003eMDR 2017\/745, Articles 83–89\u003c\/a\u003e, \u003ca href=\"https:\/\/www.lakemedelsverket.se\/sv\/medicinteknik\/folj-upp-anvandning\/rapportering-av-allvarliga-tillbud\"\u003eSwedish Medical Products Agency – serious incidents\u003c\/a\u003e, \u003ca href=\"https:\/\/health.ec.europa.eu\/medical-devices-eudamed\/overview_en\"\u003eEuropean Commission – EUDAMED status\u003c\/a\u003e, \u003ca href=\"https:\/\/health.ec.europa.eu\/medical-devices-sector\/new-regulations\/guidance-mdcg-endorsed-documents-and-other-guidance_en\"\u003eMDCG guidance\u003c\/a\u003e, and \u003ca href=\"https:\/\/eur-lex.europa.eu\/eli\/reg\/2016\/679\/oj\/swe\"\u003eGDPR\u003c\/a\u003e. The sources describe the rules, not a regulatory approval of this product.\u003c\/p\u003e\n\n\n\u003c\/div\u003e","brand":"Svenska Dokumentmallar","offers":[{"title":"Default Title","offer_id":56663327899990,"sku":"MB-MDR88-TREND-261117-V1","price":79.0,"currency_code":"SEK","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0827\/2373\/3846\/files\/01_mdr88_huvudbild_1600.png?v=1794901560","url":"https:\/\/mallbutiken.se\/en\/products\/mdr-artikel88-trendrapportering-tillbudsanalys-capa","provider":"Mallbutiken","version":"1.0","type":"link"}